Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
| Country | United States |
|---|---|
| Deadline | 2027-01-07 (46 days left) |
| Published | 2024-11-18 |
| Sectors | Health & life sciences |
| Source | Grants.gov (US) |
Summary
Funding opportunity PAR-25-070. CFDA: 93.393
The buyer, the value, the full description and the link to the official notice are available with a free account.